All In Biotech

Drug Trial Radar · NCT06791824

Study of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia

A Phase IB/II Clinical Study to Assess the Safety, Tolerability and Preliminary Efficacy of CM313(SC) Injection in Subjects With Relapsed/Refractory Aplastic Anemia

Last checked: Nov 19, 2026Latest source record: Feb 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

125

Planned (sponsor's estimate)

Start

Mar 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Jan 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, phase IB/II clinical study to evaluate the safety, tolerability and preliminary efficacy of CM313(SC) injection in patients with relapsed/refractory aplastic anemia

Conditions

  • Aplastic Anemia

Interventions

  • CM313(SC) injectionBiological

    Phase IB: CM313(SC) administered at low dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

  • CM313(SC) injectionBiological

    Phase IB: CM313(SC) administered at medium dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

  • CM313(SC) injectionBiological

    Phase IB: CM313(SC) administered at high dose according to the protocol. Phase II: CM313(SC) administered at different doses based on Phase IB's results.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE)Time frame: Up to 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.